유럽의 희귀질환 유전자 검사 시장 : 분석 및 예측(2023-2033년)

Introduction to Europe Rare Disease Genetic Testing Market

The Europe rare disease genetic testing market was valued at $1.16 billion in 2023 and is anticipated to reach $4.17 billion by 2033, witnessing a CAGR of 13.60% during the forecast period 2023-2033. The market for genetic testing in rare diseases has experienced notable growth, driven by a rising need for early identification of such conditions. The growing occurrence of rare diseases has been a pivotal factor in this growth trajectory. Moreover, there's a heightened acknowledgment and focus on early detection and prevention, particularly among pediatric populations worldwide, which is anticipated to further drive market growth.

Market Introduction

The Europe rare disease genetic testing market in Europe is witnessing substantial growth driven by several factors. Increasing awareness and advancements in genetic testing technologies have propelled demand for early detection and diagnosis of rare diseases across the continent. Additionally, the rising prevalence of rare diseases in European populations has contributed significantly to market growth. Moreover, there's a growing emphasis on early intervention and personalized medicine, further boosting the adoption of genetic testing for rare diseases. Regulatory initiatives and healthcare policies promoting accessibility to genetic testing services also play a crucial role in market development. As healthcare systems in Europe prioritize precision medicine and improved patient outcomes, the rare disease genetic testing market is poised for continued growth, offering opportunities for innovation and collaboration among stakeholders in the healthcare sector.

Market Segmentation:

Segmentation 1: by Disease Type

• Gastroenterology Disease
• Endocrine and Metabolism Disease
• Cardiovascular Disease
• Neurology Disease
• Hematology and Oncology Disease
• Dermatology Disease
• Other Diseases

Segmentation 2: by Technology

• Sanger Sequencing
• PCR
• NGS
• Microarrays
• Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Russia
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• CENTOGENE N.V.
• Eurofins Scientific SE
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Global Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.2.1 Inclusion Criteria
    • 1.1.2.2 Exclusion Criteria
  • 1.1.3 Market Overview
    • 1.1.3.1 Market Footprint
    • 1.1.3.2 Market Size and Future Growth Potential
  • 1.1.4 COVID-19 Impact on the Market
    • 1.1.4.1 Impact on Research and Clinical Operations
    • 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
• 1.2 Industry Analysis
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Legal Requirements and Framework in the U.S.
    • 1.2.1.2 Legal Requirements and Framework in Europe
      • 1.2.1.2.1 U.K.
      • 1.2.1.2.2 Spain
    • 1.2.1.3 Legal Requirements and Framework in Asia-Pacific
      • 1.2.1.3.1 Japan
      • 1.2.1.3.2 China
      • 1.2.1.3.3 India
      • 1.2.1.3.4 Taiwan
  • 1.2.2 Patent Analysis
    • 1.2.2.1 Patent Filing Trend (by Country)
    • 1.2.2.2 Patent Filing Trend (by Year)
  • 1.2.3 Funding Scenario
• 1.3 Market Dynamics
  • 1.3.1 Overview
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    • 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    • 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  • 1.3.3 Market Challenges
    • 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    • 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    • 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    • 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Europe

• 2.1 Europe Rare Disease Genetic Testing Market
  • 2.1.1 Market Dynamics
    • 2.1.1.1 Impact Analysis
  • 2.1.2 Market Sizing and Forecast
    • 2.1.2.1 Europe Rare Disease Genetic Testing Market (by Disease Type)
    • 2.1.2.2 Europe Rare Disease Genetic Testing Market (by Technology)
    • 2.1.2.3 Europe Rare Disease Genetic Testing Market (by Country)
      • 2.1.2.3.1 Germany
        • 2.1.2.3.1.1 Market Dynamics
        • 2.1.2.3.1.2 Market Size and Forecast
        • 2.1.2.3.1.2.1 Germany Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.1.2.2 Germany Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.2 U.K.
        • 2.1.2.3.2.1 Market Dynamics
        • 2.1.2.3.2.2 Market Size and Forecast
        • 2.1.2.3.2.2.1 U.K Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.2.2.2 U.K. Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.3 France
        • 2.1.2.3.3.1 Market Dynamics
        • 2.1.2.3.3.2 Market Size and Forecast
        • 2.1.2.3.3.2.1 France Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.3.2.2 France Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.4 Italy
        • 2.1.2.3.4.1 Market Dynamics
        • 2.1.2.3.4.2 Market Size and Forecast
        • 2.1.2.3.4.2.1 Italy Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.4.2.2 Italy Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.5 Spain
        • 2.1.2.3.5.1 Market Dynamics
        • 2.1.2.3.5.2 Market Size and Forecast
        • 2.1.2.3.5.2.1 Spain Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.5.2.2 Spain Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.6 Russia
        • 2.1.2.3.6.1 Market Dynamics
        • 2.1.2.3.6.2 Market Size and Forecast
        • 2.1.2.3.6.2.1 Russia Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.6.2.2 Russia Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.7 Rest-of-Europe
        • 2.1.2.3.7.1 Market Dynamics
        • 2.1.2.3.7.2 Market Size and Forecast
        • 2.1.2.3.7.2.1 Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.7.2.2 Rest-of-Europe Rare Disease Genetic Testing Market (by Technology)

3 Company Profiles

• 3.1 Overview
  • 3.1.1 CENTOGENE N.V.
    • 3.1.1.1 Company Overview
    • 3.1.1.2 Role of CENTOGENE N.V. in the Rare Disease Genetic Testing Market
    • 3.1.1.3 Financials
    • 3.1.1.4 Recent Developments
    • 3.1.1.5 Analyst Perspective
  • 3.1.2 Eurofins Scientific SE
    • 3.1.2.1 Company Overview
    • 3.1.2.2 Role of Eurofins Scientific SE in the Rare Disease Genetic Testing Market
    • 3.1.2.3 Financials
    • 3.1.2.4 Recent Developments
    • 3.1.2.5 Analyst Perspective
  • 3.1.3 QIAGEN N.V.
    • 3.1.3.1 Company Overview
    • 3.1.3.2 Role of QIAGEN N.V. in the Rare Disease Genetic Testing Market
    • 3.1.3.3 Financials
    • 3.1.3.4 Recent Developments
    • 3.1.3.5 Analyst Perspective